Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
Recruiting now · Phase 2
Conditions studied: Neuroblastoma
In brief
This is a phase II single center study to administer two courses of myeloablative consolidation chemotherapy each followed by an autologous peripheral blood stem cell (PBSC) rescue in patients with high-risk neuroblastoma who have completed induction chemotherapy (independent of this study). Ideally, patients should begin consolidation chemotherapy no later than 8 weeks after the start of Induction Cycle #5; however it is strongly recommended to begin consolidation within 4-6 weeks after the start of Induction Cycle #5.
Key facts
- Study ID
- NCT02605421
- Run by
- Masonic Cancer Center, University of Minnesota
- People needed
- 12
- Starts
- 2016-06-01
- Expected to finish
- 2026-12-01
- Last updated by the study team
- 2025-10-21
Who can join
Age: any, up to 30. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Masonic Cancer Center, University of Minnesota — Minneapolis, Minnesota, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.